Steroid sparing option for ANCA-associated vasculitis

The C5a receptor inhibitor avacopan is non-inferior to oral prednisone on a tapering schedule for the management of ANCA-associated vasculitis. The ADVOCATE trial, published in the NEJM, randomised 331 patients to either oral avacopan (30 mg twice daily) or oral prednisone (tapered from 60 mg/day to none over 21 weeks). All patients received standard remission-induction ...

Already a member?

Login to keep reading.

© 2021 the limbic